See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. For decades, advanced medical breakthroughs have followed a familiar ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
Chimeric antigen receptor T cell (CAR T) therapies have transformed the treatment of blood cancers, delivering durable responses in patients with limited options. But CAR T therapies are complex and ...
The remarkable clinical success of CAR T therapies in blood cancers has validated the promise of engineered cell therapies. But according to Adam Janvier, PhD, head of cell therapy at eXmoor Pharma, ...
A Korean research team has developed a new viral vector technology that significantly improves the production efficiency of ...
As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...
Cellares and Cabaletta Bio have reached a key clinical milestone. The companies announced April 14 dosing the first two patients with rese-cel. Cellares’ automated Cell Shuttle platform manufactured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results